You just read:

Viking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

News provided by

Viking Therapeutics, Inc.

04 Oct, 2016, 07:05 ET